Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study

Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study

Background: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is currently the standard second-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC) after previous failed gemcitabine-based therapy. This population-based study aimed to evaluate the efficac...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tai-Jan Chiu, Yung-Yeh Su, Shih-Hung Yang, Chung-Pin Li, Li-Yuan Bai, Nai-Jung Chiang, Shih-Chang Chuang, Yan-Shen Shan, De-Chuan Chan, Li-Tzong Chen, Chia-Jui Yen, Cheng-Ming Peng, Yen-Yang Chen, Jen-Shi Chen, Wen-Chi Chou
Formato: article
Lenguaje:EN
Publicado: SAGE Publishing 2021
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/4f0d6e13c91c49d18e9d3d1591cc40a2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/4f0d6e13c91c49d18e9d3d1591cc40a2

Ejemplares similares